Patents by Inventor Henry S. Friedman
Henry S. Friedman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813298Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: GrantFiled: July 5, 2022Date of Patent: November 14, 2023Assignee: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Publication number: 20220339223Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: ApplicationFiled: July 5, 2022Publication date: October 27, 2022Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Patent number: 11406677Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: GrantFiled: September 10, 2020Date of Patent: August 9, 2022Assignee: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Publication number: 20200405795Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: ApplicationFiled: September 10, 2020Publication date: December 31, 2020Applicant: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Patent number: 10799543Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: GrantFiled: July 9, 2019Date of Patent: October 13, 2020Assignee: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Patent number: 10744171Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Sequential treatment with the virus construct followed by chemotherapy drugs increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioblastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.Type: GrantFiled: March 20, 2017Date of Patent: August 18, 2020Assignee: Duke UniversityInventors: Darell D. Bigner, Matthias Gromeier, Annick Desjardins, Henry S. Friedman, Allan H. Friedman, John H. Sampson
-
Publication number: 20190343904Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: ApplicationFiled: July 9, 2019Publication date: November 14, 2019Applicant: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Patent number: 10398743Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: GrantFiled: February 9, 2017Date of Patent: September 3, 2019Assignee: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Publication number: 20190105360Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Sequential treatment with the virus construct followed by chemotherapy drugs increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioblastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.Type: ApplicationFiled: March 20, 2017Publication date: April 11, 2019Applicant: Duke UniversityInventors: Darell D. Bigner, Matthias Gromeier, Annick Desjardins, Henry S. Friedman, Allan H. Friedman, John H. Sampson
-
Publication number: 20170216382Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: ApplicationFiled: February 9, 2017Publication date: August 3, 2017Applicant: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Publication number: 20160030497Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: ApplicationFiled: November 21, 2013Publication date: February 4, 2016Inventors: Matthias GROMEIER, John H. SAMPSON, Darell D. BIGNER, Annick DESJARDINS, Henry S. FRIEDMAN
-
Patent number: 6251886Abstract: Methods are disclosed for treating cancer in a patient in need of such treating comprising administering temozolomide in an amount effective to achieve a clinical response wherein the temozolomide is administered in a microcrystalline suspension.Type: GrantFiled: December 2, 1999Date of Patent: June 26, 2001Assignee: Schering CorporationInventor: Henry S. Friedman
-
Patent number: 5695751Abstract: L-amino acid oxidase is utilized to reduce the plasma level of large neutral amino acids to allow the opportunity of increased large neutral amino acid drug transport across the blood brain barrier. Preferably anti L-amino acid oxidase antibody is administered intermediate to the L-amino acid oxidase and large neutral amino acid drug administrations to deplete L-amino acid oxidase activity once the L-amino acid oxidase has caused the large neutral amino acid drug transport improving level plasma reduction of large neutral amino acids thereby to reduce or eliminate degrading of large neutral amino acid drugs by L-amino acid oxidase. The large neutral amino acid drugs include levodopa, melphalan, L-DON, azaserine, acivicin, L-alanosine and 3-(phosphonomethyl)phenylalanines. For treatment of brain tumors, the drug administration is preferably preceded by the administration of a large neutral amino acid glutathione depleting agent, e.g., L-buthionine-SR-sulfoximine.Type: GrantFiled: September 21, 1995Date of Patent: December 9, 1997Assignees: Cornell Research Foundation, Inc., Duke UniversityInventors: Henry S. Friedman, Darell D. Bigner, Owen W. Griffith
-
Patent number: 5523084Abstract: L-amino acid oxidase is utilized to reduce plasma level of large neutral amino acids to allow the opportunity of increased melphalan transport into tumors and melphalan is administered when the plasma level of L-amino acid oxidase is sufficiently low so the gain from increased transport outweighs the loss from L-amino acid oxidase-mediated metabolism of melphalan. Preferably anti L-amino acid oxidase antibody is administered intermediate the L-amino acid oxidase and melphalan administrations to deplete L-amino acid oxidase activity once the L-amino acid oxidase has caused the melphalan transport improving plasma level reduction of large neutral amino acids thereby to reduce or eliminate degrading of melphalan by L-amino acid oxidase.Type: GrantFiled: September 7, 1994Date of Patent: June 4, 1996Assignees: Cornell Research Foundation, Inc., Duke UniversityInventors: Darell D. Bigner, Henry S. Friedman, Owen W. Griffith
-
Patent number: 5407672Abstract: L-amino acid oxidase is utilized to reduce plasma level of large neutral amino acids to allow the opportunity of increased melphalan transport into tumors and melphalan is administered when the plasma level of L-amino acid oxidase is sufficiently low so the gain from increased transport outweighs the loss from L-amino acid oxidase-mediated metabolism of melphalan.Type: GrantFiled: April 8, 1993Date of Patent: April 18, 1995Assignees: Cornell Research Foundation, Inc., Duke UniversityInventors: Owen W. Griffith, Henry S. Friedman
-
Patent number: 5407925Abstract: A method of treating human tumors is provided in which tumors are regionally treated with a cytolytic, pre-activated, bifunctional alkylating agent, namely 4-hydroperoxycyclophosphamide. The treatment is effective against a variety of tumor types within the central nervous systems.Type: GrantFiled: November 6, 1991Date of Patent: April 18, 1995Assignees: The Johns Hopkins University, Duke UniversityInventors: Darell D. Bigner, Henry S. Friedman, O. Michael Colvin